Provided by Tiger Fintech (Singapore) Pte. Ltd.

Haemonetics

64.80
-0.7200-1.10%
Post-market: 61.56-3.2400-5.00%17:58 EDT
Volume:1.16M
Turnover:75.10M
Market Cap:3.26B
PE:25.52
High:65.76
Open:65.33
Low:64.35
Close:65.52
Loading ...

IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe

Zacks
·
11 Mar

Press Release: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Dow Jones
·
11 Mar

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Business Wire
·
10 Mar

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
04 Mar

J.P. Morgan Remains a Buy on Haemonetics (HAE)

TIPRANKS
·
04 Mar

Haemonetics Names Chan Chief Operating Officer

Dow Jones
·
04 Mar

BRIEF-Haemonetics Announces Executive Leadership Updates

Reuters
·
04 Mar

Haemonetics Names Chief Operating Officer, Chief Commercial Officer

MT Newswires Live
·
04 Mar

Haemonetics announces updates to its Executive Leadership team

TIPRANKS
·
04 Mar

Haemonetics Announces Executive Leadership Updates

THOMSON REUTERS
·
04 Mar

Press Release: Haemonetics Announces Executive Leadership Updates

Dow Jones
·
04 Mar

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Business Wire
·
03 Mar

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

GlobeNewswire
·
03 Mar

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

GlobeNewswire
·
03 Mar

KalVista Pharmaceuticals’ Sebetralstat: A Game-Changer in Oral HAE Treatment with Strong Market Potential

TIPRANKS
·
03 Mar

Haemonetics Q3 Operating Income USD 59 Million

THOMSON REUTERS
·
02 Mar